This study aims at describing the IGF pathway in ACC and to explore the in vitro response to the combined treatment with a dual IGF1R/IR inhibitor (linsitinib) and the mTOR inhibitor (sirolimus) in an in vitro model of ACC using ACC cell lines. The gene discussed is IGF1R; the disease is adrenal cortex carcinoma.